Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 3/20 | 0.32 |
| ▸ | CYBB | P04839 | 1/20 | 0.32 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.32 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125404 | 1.00 | CNR2 (0.35) | CNR2HRH3GPR119TRPV3CYBB | |
| SCHEMBL1175760 | 0.92 | HRH3 (0.36) | CNR2HRH3GPR119TRPV3CYBB | |
| SCHEMBL1175758 | 0.92 | HRH3 (0.36) | CNR2HRH3GPR119TRPV3CYBB | |
| SCHEMBL4122075 | 0.87 | CNR2 (0.47) | CNR2HRH3 | |
| SCHEMBL4122082 | 0.87 | CNR2 (0.47) | CNR2HRH3 | |
| SCHEMBL1174470 | 0.87 | CNR2 (0.49) | CNR2GPR119CYBBNOX5NOX4 | |
| SCHEMBL1174472 | 0.87 | CNR2 (0.49) | CNR2GPR119CYBBNOX5NOX4 | |
| SCHEMBL4117153 | 0.83 | CNR2 (0.38) | CNR2HRH3TRPV3CYBBNOX5 | |
| SCHEMBL13798760 | 0.83 | CNR2 (0.45) | CNR2TRPV3CYBBNOX5NOX4 | |
| SCHEMBL4117157 | 0.83 | CNR2 (0.38) | CNR2HRH3TRPV3CYBBNOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CNR2 2/4885HRH3 34/4885GPR119 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.